134 related articles for article (PubMed ID: 10556576)
1. Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor.
Zhu J; Nathan C; Ding A
Biochim Biophys Acta; 1999 Sep; 1451(2-3):219-23. PubMed ID: 10556576
[TBL] [Abstract][Full Text] [Related]
2. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide.
Jin FY; Nathan C; Radzioch D; Ding A
Cell; 1997 Feb; 88(3):417-26. PubMed ID: 9039268
[TBL] [Abstract][Full Text] [Related]
3. Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages.
Ding A; Thieblemont N; Zhu J; Jin F; Zhang J; Wright S
Infect Immun; 1999 Sep; 67(9):4485-9. PubMed ID: 10456890
[TBL] [Abstract][Full Text] [Related]
4. Identification of genes involved in innate responsiveness to bacterial products by differential display.
Jin F; Nathan C; Ding A
Methods; 1998 Dec; 16(4):396-406. PubMed ID: 10049647
[TBL] [Abstract][Full Text] [Related]
5. [Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection].
Sano C; Shimizu T; Sato K; Ogasawara K; Tomioka H
Kekkaku; 1999 Jul; 74(7):563-70. PubMed ID: 10481411
[TBL] [Abstract][Full Text] [Related]
6. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function.
Yang J; Zhu J; Sun D; Ding A
Biochim Biophys Acta; 2005 Sep; 1745(3):310-7. PubMed ID: 16112212
[TBL] [Abstract][Full Text] [Related]
7. Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages.
Sano C; Shimizu T; Tomioka H
Cytokine; 2003 Jan; 21(1):38-42. PubMed ID: 12668158
[TBL] [Abstract][Full Text] [Related]
8. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice.
Nakamura A; Mori Y; Hagiwara K; Suzuki T; Sakakibara T; Kikuchi T; Igarashi T; Ebina M; Abe T; Miyazaki J; Takai T; Nukiwa T
J Exp Med; 2003 Mar; 197(5):669-74. PubMed ID: 12615907
[TBL] [Abstract][Full Text] [Related]
9. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases.
Zhang Y; DeWitt DL; McNeely TB; Wahl SM; Wahl LM
J Clin Invest; 1997 Mar; 99(5):894-900. PubMed ID: 9062347
[TBL] [Abstract][Full Text] [Related]
10. Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response.
Odaka C; Mizuochi T; Yang J; Ding A
J Immunol; 2003 Aug; 171(3):1507-14. PubMed ID: 12874244
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor.
Jin F; Nathan CF; Radzioch D; Ding A
Infect Immun; 1998 Jun; 66(6):2447-52. PubMed ID: 9596701
[TBL] [Abstract][Full Text] [Related]
12. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.
Sallenave JM; Shulmann J; Crossley J; Jordana M; Gauldie J
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):733-41. PubMed ID: 7946401
[TBL] [Abstract][Full Text] [Related]
13. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.
Taggart CC; Greene CM; McElvaney NG; O'Neill S
J Biol Chem; 2002 Sep; 277(37):33648-53. PubMed ID: 12084717
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells.
Abbinante-Nissen JM; Simpson LG; Leikauf GD
Am J Physiol; 1993 Sep; 265(3 Pt 1):L286-92. PubMed ID: 8105697
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
Henriksen PA; Hitt M; Xing Z; Wang J; Haslett C; Riemersma RA; Webb DJ; Kotelevtsev YV; Sallenave JM
J Immunol; 2004 Apr; 172(7):4535-44. PubMed ID: 15034071
[TBL] [Abstract][Full Text] [Related]
16. Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages.
Sano C; Shimizu T; Sato K; Kawauchi H; Tomioka H
Clin Exp Immunol; 2000 Jul; 121(1):77-85. PubMed ID: 10886242
[TBL] [Abstract][Full Text] [Related]
17. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils.
Sallenave JM; Si Tahar M; Cox G; Chignard M; Gauldie J
J Leukoc Biol; 1997 Jun; 61(6):695-702. PubMed ID: 9201260
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Turpin JA; Schaeffer CA; Bu M; Graham L; Buckheit RW; Clanton D; Rice WG
Antiviral Res; 1996 Mar; 29(2-3):269-77. PubMed ID: 8739605
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor.
Wright CD; Kennedy JA; Zitnik RJ; Kashem MA
Biochem Biophys Res Commun; 1999 Jan; 254(3):614-7. PubMed ID: 9920787
[TBL] [Abstract][Full Text] [Related]
20. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
Konopka K; Shine N; Pretzer E; Düzgüneş N
J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
